Avadel presents new data supporting clinical benefit with once-at-bedtime ft218 and preference for once-nightly dosing in patients with narcolepsy at chest 2021

- post-hoc responder analyses demonstrated a significantly greater proportion of patients receiving ft218 experienced reductions in weekly cataplexy attacks and improvement in mean sleep latency compared to placebo -

AVDL Ratings Summary

AVDL Quant Ranking